Eric J. Topol

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	A Generalist Learner for Multifaceted Medical Image Interpretation	2024	Hong-Yu Zhou Subathra Adithan Julián Acosta Eric J. Topol Pranav Rajpurkar
+	Digitising the outbreak	2023	Brady Page Eric J. Topol
+	Generative Artificial Intelligence in Healthcare: Ethical Considerations and Assessment Checklist	2023	Yilin Ning Salinelat Teixayavong Yuqing Shang Julian Savulescu Vaishaanth Nagaraj Di Miao Mayli Mertens Daniel Shu Wei Ting Jasmine Chiat Ling Ong Mingxuan Liu
+ PDF Chat	Sensor-based surveillance for digitising real-time COVID-19 tracking in the USA (DETECT): a multivariable, population-based, modelling study	2022	Jennifer M. Radin Giorgio Quer Jay Pandit Matteo Gadaleta Katie Baca-Motes Edward Ramos Erin Coughlin Katie Quartuccio Vik Kheterpal Leo Wolansky
+ PDF Chat	Smartphone apps in the COVID-19 pandemic	2022	Jay Pandit Jennifer M. Radin Giorgio Quer Eric J. Topol
+ PDF Chat	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands	2022	Giorgio Quer Matteo Gadaleta Jennifer M. Radin Kristian G. Andersen Katie Baca-Motes Edward Ramos Eric J. Topol Steven R. Steinhubl
+ PDF Chat	6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers	2022	Jason Cham Amitabh C. Pandey Jacob New Tridu R. Huynh Lee K. Hong Natalia Orendain Eric J. Topol Laura Nicholson
+	Passive Detection of COVID-19 with Wearable Sensors and Explainable Machine Learning Algorithms	2021	Matteo Gadaleta Jennifer M. Radin Katie Baca-Motes Edward Ramos Vik Kheterpal Eric J. Topol Steven R. Steinhubl Giorgio Quer
+ PDF Chat	Has SARS-CoV-2 reached peak fitness?	2021	Roberto Burioni Eric J. Topol
+ PDF Chat	Pre-existing health conditions and severe COVID-19 infection: Analysis of commercial health insurance data from 690,000 infected patients	2021	Nathan E. Wineinger Victoria Li Jill Waalen Eric J. Topol
+ PDF Chat	Assessing the human immune response to SARS-CoV-2 variants	2021	Roberto Burioni Eric J. Topol
+	Prevalence of Asymptomatic SARS-CoV-2 Infection	2021	Daniel P. Oran Eric J. Topol
+	Wearable sensor data and self-reported symptoms for COVID-19 detection	2020	Giorgio Quer Jennifer M. Radin Matteo Gadaleta Katie Baca-Motes Lauren Ariniello Edward Ramos Vik Kheterpal Eric J. Topol Steven R. Steinhubl
+	Passive Monitoring of Physiological Data and Self-reported Symptoms to Detect Clusters of People with COVID-19	2020	Giorgio Quer Jennifer M. Radin Matteo Gadaleta Katie Baca-Motes Lauren Ariniello Edward Ramos Vik Kheterpal Eric J. Topol Steven R. Steinhubl
+	Applications of digital technology in COVID-19 pandemic planning and response	2020	Sera Whitelaw Mamas A. Mamas Eric J. Topol Harriette G.C. Van Spall
+ PDF Chat	Prevalence of Asymptomatic SARS-CoV-2 Infection	2020	Daniel P. Oran Eric J. Topol
+ PDF Chat	Personalized medicine: risk prediction, targeted therapies and mobile health technology	2014	Daniel F. Hayes Hugh S. Markus Richard David Leslie Eric J. Topol
+ PDF Chat	Pharm-Econogenomics: A New Appraisal	2013	Paddy Barrett Eric J. Topol
+ PDF Chat	The N-Of-1 Clinical Trial: The Ultimate Strategy For Individualizing Medicine?	2011	Elizabeth O. Lillie Bradley Patay Joel Diamant Brian F. Issell Eric J. Topol Nicholas J. Schork
+ PDF Chat	Pharmacy Benefit Managers, Pharmacies, and Pharmacogenomic Testing: Prescription for Progress?	2010	Eric J. Topol
+ PDF Chat	Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials	2010	Nicholas J. Schork Eric J. Topol
+	A matter of life and death? The Heart Protection Study and protection of clinical trial participants	2003	Raymond Q. Migrino Eric J. Topol
+	Dosing regimen of reteplase and costeffectiveness	2001	Eric J. Topol
+ PDF Chat	Systematic adjudication of myocardial infarction end-points in an international clinical trial	2001	Kenneth W. Mahaffey Robert A. Harrington K. Martijn Akkerhuis Neal S. Kleiman Lisa G. Berdan Brian S. Crenshaw Barbara E. Tardiff Christopher B. Granger Ingrid DeJong Manju Bhapkar
+	Predictors of abrupt closure and consequences of emergency endpoints in the IMPACT II trial	1996	Bruce A. Bergelson Charles J. Davidson Gail E. Hafley Russell J. Ivanhoe James J. Ferguson Barbara E. Tardiff Kenneth W. Mahaffey A. Michael Lincoff James T. Tcheng Robert M. Califf
+ PDF Chat	More on the GUSTO Trial	1994	Eric J. Topol Robert M. Califf Kerry L. Lee

Common Coauthors

Coauthor	Papers Together
Giorgio Quer	6
Jennifer M. Radin	6
Matteo Gadaleta	5
Katie Baca-Motes	5
Steven R. Steinhubl	5
Edward Ramos	5
Vik Kheterpal	4
Robert M. Califf	3
Lauren Ariniello	2
Kenneth W. Mahaffey	2
Jay Pandit	2
Nicholas J. Schork	2
Barbara E. Tardiff	2
Roberto Burioni	2
Daniel P. Oran	2
Victoria Li	1
Kristian G. Andersen	1
K. Martijn Akkerhuis	1
Gail E. Hafley	1
Daniel Shu Wei Ting	1
Kerry L. Lee	1
Tridu R. Huynh	1
Richard David Leslie	1
Neal S. Kleiman	1
Roger Vaughan	1
Yilin Ning	1
Paddy Barrett	1
Erin Coughlin	1
Ingrid DeJong	1
Elizabeth O. Lillie	1
Laura Nicholson	1
Ramón Corbalon	1
Joseph J.�Y. Sung	1
Mayli Mertens	1
Jacob New	1
Sera Whitelaw	1
Hugh S. Markus	1
Mamas A. Mamas	1
Harriette G.C. Van Spall	1
Robert A. Harrington	1
Bruce A. Bergelson	1
Natalia Orendain	1
Michael Dunn	1
Daniel F. Hayes	1
Nathan E. Wineinger	1
Jaap W. Deckers	1
Manju Bhapkar	1
Raymond Q. Migrino	1
James T Tcheng	1
Katie Quartuccio	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Pre-symptomatic detection of COVID-19 from smartwatch data	2020	Tejaswini Mishra Meng Wang Ahmed A. Metwally Gireesh K. Bogu Andrew Brooks Amir Bahmani Arash Alavi Alessandra Celli Emily Higgs Orit Dagan‐Rosenfeld	4
+ PDF Chat	Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing	2020	Luca Ferretti Chris Wymant Michelle Kendall Lele Zhao Anel Nurtay Lucie Abeler‐Dörner Michael Parker David Bonsall Christophe Fraser	4
+	Wearable sensor data and self-reported symptoms for COVID-19 detection	2020	Giorgio Quer Jennifer M. Radin Matteo Gadaleta Katie Baca-Motes Lauren Ariniello Edward Ramos Vik Kheterpal Eric J. Topol Steven R. Steinhubl	4
+ PDF Chat	Prevalence of Asymptomatic SARS-CoV-2 Infection	2020	Daniel P. Oran Eric J. Topol	3
+ PDF Chat	Assessment of physiological signs associated with COVID-19 measured using wearable devices	2020	Aravind Natarajan Hao-Wei Su Conor Heneghan	3
+ PDF Chat	Analyzing changes in respiratory rate to predict the risk of COVID-19 infection	2020	Dean J. Miller John V. Capodilupo Michele Lastella Charli Sargent Gregory D. Roach Victoria H. Lee Emily R. Capodilupo	3
+	Prevalence of Asymptomatic SARS-CoV-2 Infection	2021	Daniel P. Oran Eric J. Topol	3
+ PDF Chat	Feasibility of continuous fever monitoring using wearable devices	2020	Benjamin L. Smarr Kirstin Aschbacher Sarah M. Fisher Anoushka Chowdhary Stephan Dilchert Karena Puldon Adam Rao Frederick Hecht Ashley E. Mason	2
+ PDF Chat	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands	2022	Giorgio Quer Matteo Gadaleta Jennifer M. Radin Kristian G. Andersen Katie Baca-Motes Edward Ramos Eric J. Topol Steven R. Steinhubl	2
+ PDF Chat	Detecting pathogen exposure during the non-symptomatic incubation period using physiological data	2017	Lauren Milechin Shakti K. Davis Tejash Patel Mark Hernandez Greg Ciccarelli Steven J. Schwartz Siddharth Samsi Lisa E. Hensley Arthur J. Goff John C. Trefry	2
+ PDF Chat	Characterizing COVID-19 and Influenza Illnesses in the Real World via Person-Generated Health Data	2020	Allison Shapiro Nicole Marinsek Ieuan Clay Ben Bradshaw Ernesto Ramirez Jae Min Andrew D. Trister Yuedong Wang Tim Althoff Luca Foschini	2
+ PDF Chat	Improving State-Level Influenza Surveillance by Incorporating Real-Time Smartphone-Connected Thermometer Readings Across Different Geographic Domains	2019	Aaron C. Miller Ryan A. Peterson Inder Singh Sarah Pilewski Philip M. Polgreen	2
+	Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study	2020	Qin-Long Jing Ming-Jin Liu Zhou-Bin Zhang Li-Qun Fang Jun Yuan An-Ran Zhang Natalie E. Dean Lei Luo Meng-Meng Ma Ira M. Longini	2
+	Learning from Large-Scale Wearable Device Data for Predicting the Epidemic Trend of COVID-19	2020	Guokang Zhu Jia Li Zi Yang Meng Yi Yu Yanan Li Xiao Tang Yuling Dong Guangxin Sun Rui Zhou Hui Wang	2
+ PDF Chat	Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study	2020	Joseph T. Wu Kathy Leung GM Leung	2
+ PDF Chat	The Natural History and Transmission Potential of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection	2020	Nguyễn Văn Vĩnh Châu Vo Thanh Lam Nguyen Thanh Dung Lam Minh Yen Ngo Ngọc Quang Minh Le Manh Hung Nghiêm My Ngoc Nguyen Tri Dung Dinh Nguyen Huy Man Lam Anh Nguyet	2
+ PDF Chat	Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections	2020	Quanxin Long Xiao-Jun Tang Q L Shi Qin Li Haijun Deng Jun Yuan Jieli Hu Wei Xü Yong Zhang Fa-Jin Lv	2
+	A statistical model for the “N-of-1” study	1990	James Rochon	1
+	Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment	1997	Deborah R. Zucker Christopher H. Schmid Martin McIntosh Ralph B. D’Agostino Harry P. Selker J. Lau	1
+	Testing drug response in the presence of genetic information: sampling issues for clinical trials	2000	Lon R. Cardon Ramana M. Idury Timothy Harris John S. Witte Robert C. Elston	1
+	Limitations of Applying Summary Results of Clinical Trials to Individual Patients	2007	David M. Kent Rodney A. Hayward	1
+	Population Marginal Means in the Linear Model: An Alternative to Least Squares Means	1980	S. R. Searle F. M. Speed George A. Milliken	1
+	Cross-Over Trials in Clinical Research	1994	Stephen Senn	1
+	Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials	1993	Michael S. Simberkoff Pamela Hartigan John D. Hamilton Daniel Deykin Mitchell H. Gail John G. Bartlett Paul M. Feorino Robert Redfield Richard Roberts Dorothea Collins	1
+	Failure to Reach the Goal of Measles Elimination	1994	Gregory A. Poland	1
+ PDF Chat	N-of-1 Trials: A New Future?	2010	Eric B. Larson	1
+	Using N-of-1 Trials to Improve Patient Management and Save Costs	2010	Paul Scuffham Jane Nikles Geoffrey Mitchell Michael Yelland Norma Vine Christopher J. Poulos Peter I. Pillans Guy Bashford Chris Del Mar Philip J. Schlüter	1
+ PDF Chat	What Ever Happened to N‐of‐1 Trials? Insiders' Perspectives and a Look to the Future	2008	Richard L. Kravitz Naihua Duan Edmund J. Niedzinski M. Cameron Hay Saskia Subramanian Thomas S. Weisner	1
+ PDF Chat	N of 1 trials in diabetes: making individual therapeutic decisions	2008	Απόστολος Τσάπας David R. Matthews	1
+	Are Brand-Name and Generic Warfarin Interchangeable? Multiple N-of-1 Randomized, Crossover Trials	2005	Jennifer Pereira Anne Holbrook Lisa Dolovich Charles H. Goldsmith Lehana Thabane James Douketis Mark Crowther Shannon M. Bates Jeffrey S. Ginsberg	1
+	Single-Case Experimental Designs	1985	Michel Hersen	1
+	Clinical Trials and Rare Diseases	2010	Joachim Gerß Wolfgang Köpcke	1
+ PDF Chat	Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting	2012	Lisa M. McShane Daniel F. Hayes	1
+	A Multiple Testing Procedure for Clinical Trials	1979	Peter C. O’Brien Thomas R. Fleming	1
+	Impact of Influenza Treatment with Oseltamivir on Health, Sleep and Daily Activities of Otherwise Healthy Adults and Adolescents	2006	Robert Bettis Dominick Iacuzio Thomas Jung Rudolf Fuchs R Aultman Marlene Gyldmark	1
+	The<i>n</i>-of-1 Randomized Controlled Trial: Clinical Usefulness	1990	Gordon H. Guyatt	1
+	The study of candidate genes in drug trials: sample size considerations	1999	Robert C. Elston Ramana M. Idury Lon R. Cardon Jay B. Lichter	1
+ PDF Chat	Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials	2004	Richard Simon Aboubakar Maitournam	1
+ PDF Chat	Adaptive design methods in clinical trials – a review	2008	Shein‐Chung Chow Mark Chang	1
+	Statistical issues in Studies of Individual Response	1988	David J. Spiegelhalter	1
+ PDF Chat	Pharmacy Benefit Managers, Pharmacies, and Pharmacogenomic Testing: Prescription for Progress?	2010	Eric J. Topol	1
+	Policies for study monitoring and interim reporting of results.	1987	S J Green Thomas R. Fleming Judith R. OʼFallon	1
+	Planned interim analysis and its role in cancer clinical trials.	1987	Nancy L. Geller	1
+ PDF Chat	Combining Healthcare-Based and Participatory Approaches to Surveillance: Trends in Diarrheal and Respiratory Conditions Collected by a Mobile Phone System by Community Health Workers in Rural Nepal	2016	David J. Meyers Al Ozonoff Ashma Baruwal Sami Pande A. Phani Harsha Ranju Sharma Dan Schwarz Ryan Schwarz Deepak Bista Scott Halliday	1
+	Using N-of-1 Trials in Evidence-Based Clinical Practice	2009	Απόστολος Τσάπας	1
+	Validation of pharmacogenomic biomarker classifiers for treatment selection	2006	Richard Simon	1
+	Monitoring clinical trials. Dissemination of decisions on interim analyses needs wider debate.	2001	Sheila M. Bird	1
+	Consistent feature attribution for tree ensembles	2017	Scott Lundberg Su‐In Lee	1
+	100 Years of Medical Countermeasures and Pandemic Influenza Preparedness	2018	Barbara Jester Timothy M. Uyeki Anita Patel Lisa M. Koonin Daniel B. Jernigan	1
+ PDF Chat	Public health for the people: participatory infectious disease surveillance in the digital age	2014	Oktawia Wójcik John S. Brownstein Rumi Chunara Michael A. Johansson	1